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CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; CLL = chronic lymphocytic leukaemia; HACA = human antichimeric antibody;
NHL = non-Hodgkin’s lymphoma; RA = rheumatoid arthritis.
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Introduction
The chimeric monoclonal antibody rituximab, which targets
the CD20 antigen on B lymphocytes, has been used
extensively in the treatment of B cell malignancies. To
date, more than 300000 patients with non-Hodgkin’s lym-
phoma (NHL), chronic lymphocytic leukaemia (CLL), and
other B cell diseases have been treated with rituximab.
Data from numerous clinical trials of rituximab adminis-
tered as a single agent or in combination with numerous
chemotherapies have been reported, and the safety profile
of the agent is well established [1].
In rheumatoid arthritis (RA) B lymphocytes have been
implicated in the pathogenesis of rheumatoid synovitis.
The precise role of B cells in RA has not been elucidated,
but potential mechanisms include an antigen-presenting
function, secretion of proinflammatory cytokines, produc-
tion of rheumatoid factor, and costimulation of T cells
[2,3]. In this context, B cell depletion with rituximab has
recently emerged as a potential treatment option for
patients with RA. Initial pilot studies reported clinically sig-
nificant improvements in patients with RA following ritux-
imab therapy [4,5], and a randomized phase II study in
161 patients has recently reported 24-week data that
confirm the activity of rituximab in this indication [6]. In the
clinical studies to date, rituximab has been well tolerated
by patients with RA, with no major treatment related
adverse events observed [4,5]. However, it is important to
consider whether the safety profile in patients with B cell
malignancies is relevant to patients with RA, because rela-
tively few patients with RA have been treated with ritux-
imab. The present review summarizes the safety of
rituximab in the treatment of patients with B cell malignan-
cies and considers the implications for use of the agent in
the treatment of RA.
Administration of rituximab
Standard rituximab monotherapy for NHL consists of four,
once weekly infusions of 375mg/m2. The drug is infused
at an initial rate of 50mg/hour, escalating to a maximum of
400mg/hour in 50mg increments every 30 min, providing
hypersensitivity or infusion related reactions do not occur.
Provided that the first infusion is well tolerated, subse-
quent infusions can be started at 100mg/hour [7]. Other
dose schedules have also been used, including eight
once-weekly doses [8], maintenance therapy with a single
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Abstract
The chimeric anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of
B cell malignancies, and more recently it has emerged as a potential treatment for rheumatoid arthritis
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tolerated in a variety of settings, with mild-to-moderate infusion related reactions following the first
infusion being the most common adverse event. Current data suggest that the safety profile of
rituximab in patients with RA is similar to that in oncology, but that the adverse events are less frequent
and less severe in patients with RA.
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dose every 2 months [9] or four doses every 6 months [10],
and various regimens used in combination with chemother-
apy. Generally, rituximab has been administered with each
cycle of chemotherapy in this setting. In patients with CLL,
rituximab has been administered in higher or more frequent
doses, up to 2250mg/m2 weekly [11] or 375mg/m2 three
times weekly [12]. Regardless of the dose schedule, the
method of administration is as outlined above.
The current dosing regimen for rituximab in RA, as used in
randomized controlled trials, comprises two infusions of a
fixed dose of 1000 mg rituximab, administered 2 weeks
apart.
Safety of rituximab
The safety profile of rituximab monotherapy was described
in full in the pivotal phase III study in relapsed and refrac-
tory indolent NHL [13]. The pattern of adverse events has
been consistent in numerous subsequent studies in both
indolent and aggressive NHL [10,14–19].
By far the most common adverse events during or follow-
ing rituximab therapy are mild-to-moderate infusion related
reactions, consisting of a range of symptoms including
fever, chills and rigors, sometimes accompanied by
hypotension and dyspnoea (Table 1). These are related to
the rate of rituximab infusion, and usually occur within
2 hours of the initial infusion. These symptoms generally
resolve quickly and the incidence decreases markedly with
subsequent rituximab infusions (Fig.1) [20]. Premedica-
tion with acetaminophen (paracetamol) and an antihista-
mine such as diphenhydramine can reduce the incidence
and severity of infusion related reactions. The infusion
related reactions may partly be caused by release of cellu-
lar contents from lysed malignant cells (cytokine-release
syndrome), and thus are less likely to occur in patients
with RA.
Grade 3/4 treatment related adverse events are uncom-
mon with rituximab monotherapy, but rare instances of
severe infusion related reactions or tumour lysis syndrome
have been recorded, and in some instances these have
been fatal [21]. Patients at risk for tumour lysis syndrome
(those with high tumour burden and/or circulating malig-
nant cells) require careful monitoring of fluid and elec-
trolyte balance, and prophylactic treatment as necessary.
Patients with pulmonary and/or cardiac disorders also
require careful monitoring. Severe adverse events follow-
ing rituximab therapy are most commonly tumour related
and thus are less likely to occur in patients with RA.
More recently, as the worldwide database of patients
treated with rituximab has expanded, severe mucocuta-
neous reaction has been identified as another, very rare
adverse event that may be associated with rituximab
administration [21], and a note to this effect has been
added to the package insert. In more than 125000
patients, however, only 20 cases and 8 deaths have been
reported.
The higher or more frequent doses of rituximab that have
been administered in patients with CLL do not appear to
change the adverse event profile. At weekly doses up to
2250mg/m2 [11], or with administration of 375mg/m2
Table 1
Adverse events occurring in 10% of patients or more in the
pivotal study of single-agent rituximab in relapsed and
refractory indolent lymphoma
Number of patients
Adverse event Grade 1/2 Grade 3 Grade 4 %
Fever 84 – – 43
Chills 51 2 – 28
Nausea 34 1 – 18
Headache 26 1 – 14
Angio-oedema 27 1 – 14
Asthenia 25 – – 13
Pruritus 21 1 – 13
Pain 22 – – 11
Rash 16 – – 10
Hypotension 18 1 – 10
Anaemia 1 1 – 10
From McLaughlin and coworkers [13]. Reprinted with permission from
the American Society of Clinical Oncology.
Figure 1
Incidence of treatment related adverse events in the pivotal study of
rituximab in relapsed and refractory indolent non-Hodgkin’s lymphoma,
stratified by infusion number. From McLaughlin and coworkers [13].
Reprinted with permission from the American Society of Clinical
Oncology.
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three times per week for 4 weeks [12], the adverse event
profile was similar to that with the standard administration
schedule; infusion related reactions were the most
common adverse events and grade 3/4 adverse events
were uncommon. Similarly, several studies have now
demonstrated that multiple courses of rituximab do not
result in an increased incidence of adverse events, either
with retreatment on progression [22] or extended ‘mainte-
nance’ therapy to prolong remission [9,10,19]. Thus, there
is no reason to believe that the dose schedule being
studied in RA is likely to result in a different or more
serious adverse event profile.
These predictions have been borne out by 24-week data
from a double blind, placebo controlled randomized study
evaluating the safety and efficacy of rituximab in 161
patients with RA [6,23]. Patients were randomized into
four groups, and received methotrexate plus placebo infu-
sion, rituximab alone, rituximab plus methotrexate, or ritux-
imab plus cyclophosphamide. Patients in the three
rituximab groups received two infusions of 1000mg,
2 weeks apart.
Adverse event profiles for patients receiving rituximab
(n=121) or placebo infusion (n=40) were compared
(Table 2). Adverse events in patients with RA receiving rit-
uximab were similar to those previously observed in
patients with B cell malignancies, except that the overall
incidence was substantially lower (only 36% of patients
experienced an adverse event during the first infusion, as
compared with 74% of patients in the pivotal trial in NHL
[13]). Adverse events were also generally less severe in
patients with RA; no serious treatment related adverse
events were reported, and the majority of adverse events
were mild-to-moderate infusion related reactions. Notably,
the incidence of adverse events was markedly decreased
following the second infusion compared with the first, so
that with the second infusion the incidence of adverse
events did not differ between the placebo and rituximab
groups.
Because rituximab targets all CD20 positive cells, includ-
ing normal B cells, administration of the drug is followed
by a rapid drop in peripheral B lymphocyte count, which
persists for 6–12 months [24]. The drop in B lymphocyte
count is not accompanied by any increase in the incidence
of infections, however, and serum immunoglobulin levels
are maintained in the majority of patients with B cell malig-
nancies [13]. With the extended rituximab dosing sched-
ules used to prolong remission in indolent NHL, peripheral
B cells remain undetectable for longer than 2 years, with
no rise in the incidence of infections.
As expected, patients with RA receiving rituximab experi-
enced a rapid depletion of B cells from the circulation.
However, only small decreases in immunoglobulin levels
were seen, and mean immunoglobulin levels remained
within normal limits throughout treatment [25]. The great-
est proportional change was in IgM isotype, which corre-
lated with falls in total rheumatoid factor.
Combination treatment with rituximab and a variety of
chemotherapeutic agents has been widely evaluated in
NHL and CLL. As expected on the basis of the nonover-
lapping toxicities, these combinations have been well tol-
erated, with safety profiles not significantly different from
those seen with chemotherapy alone [26–28]. A double
blind, randomized study of rituximab plus chemotherapy
versus chemotherapy alone in aggressive NHL has con-
firmed these findings [29]. The most common difference
between chemotherapy alone and immunochemotherapy
with rituximab has been the incidence of mild-to-moderate
infusion related reactions, and no unexpected adverse
events have been identified. Table 3 shows the incidence
of grade 3/4 adverse events in 399 patients with aggres-
sive NHL treated with CHOP (cyclophosphamide, doxoru-
bicin, vincristine and prednisone) chemotherapy or
rituximab plus CHOP. On the basis of these experiences,
it seems likely that combinations of rituximab and cytotoxic
agents that may be used in the treatment of RA (e.g.
methotrexate or cylophosphamide) will not result in
increased or unexpected toxicity.
Anti-immunoglobulin responses
Because rituximab is a human/mouse chimeric antibody,
there is a theoretical risk for generation of human
antichimeric antibodies (HACAs). Although a low inci-
Table 2
Adverse events reported during the first and second rituximab
or placebo infusions in patients with rheumatoid arthritis
First infusion Second infusion
Rituximab Rituximab
Adverse event Placebo (1000mg) Placebo (1000mg)
Any adverse event 30 36 15 17
Transient hypotension 20 13 10 12
Transient hypertension 10 9 5 3
Flushing –4–1
Pruritus –6––
Rash –4––
Dyspnoea –3––
Pharynx discomfort –3––
Pyrexia –3––
Headache –2––
Hypotension/hypertension were defined as an increase/decrease in
systolic or diastolic pressure of more than 30 mmHg. Values are
expressed as percentages. Data from Szczepan ’ski and coworkers [23].S15
dence of HACA responses in patients with B cell malig-
nancies (<1%) has been reported by some investigators,
these have rarely been associated with any clinical symp-
toms [30]. No instances of significant HACA responses
have been reported in RA patients to date.
Conclusion
Experience in treatment of more than 300000 patients
with B cell malignancies has demonstrated that infusions
of rituximab are well tolerated, with mild-to-moderate infu-
sion related reactions being the most common adverse
events reported. This adverse event profile has been
observed for rituximab when used in a variety of settings,
including extended dosing, retreatment, and in combina-
tion with various chemotherapy regimens. Thus, although
rituximab is administered using a different dose schedule
in patients with RA in comparison with the schedules used
in oncology, it appears reasonable to expect a similar
pattern of adverse events.
Clinical experience in patients with RA to date has con-
firmed this. Mild-to-moderate infusion related reactions are
the main adverse events, although the overall incidence of
adverse events associated with the first infusion is lower,
and adverse events are generally less severe than are
usually seen in patients with haematological malignancies.
The lower incidence and severity in RA may reflect the fact
that these patients do not experience the cytokine release
syndrome caused by tumor cell lysis in patients with B cell
malignancies.
In conclusion, rituximab is a well tolerated therapy for
patients with B cell malignancies. In addition to the two-
dose schedule already evaluated in RA, experience from
the oncology setting suggests that different dose sched-
ules, retreatment, and combination with other therapies
will also be well tolerated, and may further improve the effi-
cacy of this novel agent.
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